FONT-SIZE Plus   Neg

Idenix Pharma Says IDX184 Placed On Partial Clinical Hold By FDA - Quick Facts

Idenix Pharmaceuticals Inc. (IDIX) announced that it received verbal notice from the U.S. Food and Drug Administration or FDA that a partial clinical hold has been placed on IDX184, the Company's nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus (HCV).

As a result of the recent occurrence of a serious cardiac-related adverse event encountered with a competitor's nucleotide polymerase inhibitor for the treatment of HCV, the FDA has expressed an interest in further reviewing the safety of IDX184 and has placed IDX184 on partial clinical hold.

In previous clinical trials as well as the ongoing phase IIb clinical trial of IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV), there has been no evidence to date of cardiotoxicity in patients dosed with IDX184 with PegIFN/RBV beyond that seen with PegIFN/RBV alone. There are currently no patients receiving IDX184 worldwide.

The company noted that the FDA has requested additional data on patients treated with IDX184. Patient safety is our main concern and Idenix will immediately begin work to comply with the FDA request and expects to submit these data to the FDA in the coming weeks.

The company noted that it intends to have an ongoing discussion with the FDA following the submission of this data.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Railroad operator CSX Corp. (CSX), Tuesday reported a slight drop in profit for the third quarter, as revenues dropped 9 percent hurt largely by lower coal freight revenues. Nevertheless, earnings for the quarter trumped Wall Street estimates, while revenues fell short. Jacksonville, Florida-based... Intel Corp. (INTC), the world's biggest chipmaker, Tuesday reported a drop in profit for the third quarter, as personal computer sales continue to decline. Intel generates a chunk of its revenues by selling chips for computers, however, the company has been negatively impacted by slowing demand for... Earnings at banking giant JP Morgan Chase (JPM) jumped more than 20% compared to last year, despite a decline in revenue. The firm's bottom line received a boost from about $2 billion in tax benefits.
comments powered by Disqus
Follow RTT